Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: A novel cytoprotective role of aspirin in acute myocardial infarction

Cardiovascular Research

Volumn 99, Issue 1, 2013, Pages 137-145

  Chang, Po Yuan ^a   Chen, Yi Jie ^b   Chang, Fu Hsiung ^b   Lu, Jonathan ^c   Huang, Wen Huei ^b   Yang, Tzu Ching ^b   Lee, Yuan Teh ^a   Chang, Shwu Fen ^d   Lu, Shao Chun ^b   Chen, Chu Huang ^c,e,f,g  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aspirin; DNA methylation; Genes; Lipoproteins; Myocardial infarction

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6 HYDROXYMETHYL CHIRO INOSITOL 2, 2, 2 METHYL 3, 2 OCTADECYL TIN GLYCEROCARBONATE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ANION EXCHANGE CHROMATOGRAPHY; APOPTOSIS; ARTICLE; ATHEROGENESIS; CELL FUNCTION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DNA SYNTHESIS; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; EPIGENETICS; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN CORONARY ARTERY ENDOTHELIAL CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ASPIRIN; DNA METHYLATION; GENES; LIPOPROTEINS; MYOCARDIAL INFARCTION;

AGED; APOPTOSIS; ASPIRIN; BASE SEQUENCE; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; CELL SURVIVAL; CELLS, CULTURED; CORONARY ARTERY DISEASE; CORONARY VESSELS; CPG ISLANDS; CYTOPROTECTION; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; ENDOTHELIAL CELLS; EPIGENESIS, GENETIC; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; SCAVENGER RECEPTORS, CLASS E; TRANSFECTION; UP-REGULATION;

EID: 84879406490     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt062     Document Type: Article

References (34)

1. Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation 2003;108:III28-III37 (Pubitemid 37296531)
2. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809-1817
3. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-959
4. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997;272:9962-9970 (Pubitemid 27171667)
5. Noon JP, Walker BR, Hand MF, Webb DJ. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res 1998; 38:480-484 (Pubitemid 28294166)
6. Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein (a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999;274:34111-34115 (Pubitemid 129511746)
7. Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004;15:329-335 (Pubitemid 38716567)
8. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003;107: 2102-2108 (Pubitemid 36532191)
9. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ et al. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol 2003;23:1083-1090 (Pubitemid 36713565)
10. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 2008;49:33-47
11. Chen HH, Hosken BD, Huang M, Gaubatz JW, Myers CL, Macfarlane RD et al. Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic. J Lipid Res 2007;48:177-184 (Pubitemid 46052909)
12. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57:158-166
13. Chen CH, Lu J, Chen SH, Huang RY, Yilmaz HR, Dong J et al. Effects of electronegative VLDL on endothelium damage in metabolic syndrome. Diabetes Care 2012;35: 648-653
14. Ke LY, Engler DA, Lu J, Matsunami RK, Chan HC, Wang GJ et al. Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure Appl Chem 2011;83:1731-1740
15. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007; 100:1634-1642 (Pubitemid 46897266)
16. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-627
17. Mehta JL, Chen J, Yu F, Li DY. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 2004; 64:243-249 (Pubitemid 39361685)
18. Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 2000;101:171-177 (Pubitemid 30044257)
19. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD et al. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation 2001;104:588-593 (Pubitemid 32738130)
20. Medina MA. Hyperhomocysteinemia and occlusive vascular disease: an emergent role for fibroblast growth factor 2. Circ Res 2008;102:869-870 (Pubitemid 351591542)
21. Chen CH, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2004;2:33-43 (Pubitemid 38855013)
22. Manning JR, Carpenter G, Porter DR, House SL, Pietras DA, Doetschman T et al. Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATPsensitive potassium channels. Growth Factors 2012;30:124-139
23. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH et al. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 2008;102: 933-941 (Pubitemid 351591555)
24. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM et al 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-2306
25. Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized low-density lipoprotein inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin Exp Pharmacol Physiol 2003;30:665-670 (Pubitemid 37222744)
26. Shibata F, Baird A, Florkiewicz RZ. Functional characterization of the human basic fibroblast growth factor gene promoter. Growth Factors 1991;4:277-287
27. Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972;61: 379-385
28. Obata JE, Nakamura T, Kitta Y, Kodama Y, Sano K, Kawabata K et al. Treatment of acute myocardial infarction with sirolimus-eluting stents results in chronic endothelial dysfunction in the infarct-related coronary artery. Circ Cardiovasc Interv 2009;2: 384-391
29. Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 1997;79:159-192
30. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321: 209-213 (Pubitemid 16016411)
31. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M et al. Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig Dis Sci 2010; 55:54-59
32. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-1218
33. Minar E, Ahmadi A, Koppensteiner R, Maca T, Stumpflen A, Ugurluoglu A et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995;91:2167-2173
34. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.